FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

PRINCETON, N.J.–(BUSINESS WIRE)– April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall

Read more

Pembrolizumab May Be Preferable to Chemo in Certain Patients

NEW YORK (Reuters Health) – Pembrolizumab may have an edge on chemotherapy for microsatellite instability-high (MSI-H) advanced gastric or gastroesophageal-junction

Read more